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    The TNF receptor superfamily (TNFRSF) comprises   30 genes 
whose products are Type I transmembrane glycoproteins (  Ware, 
2003  ). Receptor occupancy by the corresponding TNF-like lig-
ands affects a host of biological processes, including innate 
and adaptive immunity, cell death versus survival (homeostasis), 
and lymphoid development. Receptor engagement results in the 
assembly of signaling complexes that include enzymes that are 
also adaptors, one example of which is TNF receptor-associated 
factor 2 (TRAF2), a RING-containing ubiquitin protein ligase 
(E3) that recruits cellular inhibitors of apoptosis (cIAP) 1 and 2 
to the signaling complex (  Rothe et al., 1995  ). cIAP1 and cIAP2 
themselves are RING-containing E3s (  Yang et al., 2000  ), and 
the interplay between these two protein families and other mol-
ecules in the receptor complex is critical in the propagation of 
downstream signals. 
  It has recently been appreciated that acute down-regulation 
of cIAPs is fatal for some tumor cell lines. Smac/DIABLO is a 
mitochondrial protein that, in stressed cells, is released into the 
Smac mimetics (inhibitor of apoptosis [IAP] antagonists) 
are synthetic reagents that kill susceptible tumor cells by 
inducing degradation of cellular IAP (cIAP) 1 and cIAP2, 
nuclear factor     B activation, tumor necrosis factor (TNF) 
     production, TNF receptor 1 occupancy, and caspase-8 
activation. In this issue of   The Journal of Cell Biology  , 
Vince et al. (see p. 171) report remarkable similarities in 
the events leading to tumor cell death triggered by the 
cytokine TWEAK (TNF-like weak inducer of apoptosis) 
and IAP antagonists. Although the mechanistic details 
differ, a common and necessary feature that is also 
shared by TNF receptor 2 signaling is reduction in the 
level of cIAP1 and, in some cases, cIAP2 and TNF receptor-
associated factor 2. These ﬁ  ndings not only extend our 
appreciation of how cell death pathways are kept in 
check in tumors, they reinforce the possible utility of in-
duced cIDE (cIAP deﬁ  ciency) in the selective elimination 
of neoplastic cells.
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cytosol and binds BIR (Baculovirus IAP repeat) domains of 
IAPs such as XIAP, displacing active caspases (  Shiozaki and 
Shi, 2004  ). Based on the notion that the freed caspases would 
kill the cell, several groups have created IAP antagonists: small 
peptides or compounds that, like Smac, bind IAPs and interfere 
with caspase interaction. Although the IAP antagonists indeed 
did kill some tumor cell lines, the mechanism of action was 
completely unexpected (  Gaither et al., 2007  ;   Petersen et al., 
2007  ;   Varfolomeev et al., 2007  ;   Vince et al., 2007  ). In sensitive 
cells, the IAP antagonists caused autoubiquitination and protea-
somal degradation of cIAP1 and cIAP2 rather than the expected 
target, XIAP. Acute reduction in these IAPs activated both the 
canonical and noncanonical NF-    B pathways and caused auto-
crine TNF    production, which in turn led to TNFR1 occupancy, 
caspase-8 activation, and cell death. Because most cells lines 
are insensitive to killing by TNF     in the absence of a sensitizing 
agent such as cycloheximide, it was a logical inference that the 
IAP antagonists must also confer sensitization to exogenous 
TNF    , which proved to be the case. 
 TNF-like weak inducer of apoptosis (TWEAK;  TNFSF12 ) 
was described in 1997 (  Chicheportiche et al., 1997  ), and its re-
ceptor,  the  non – death  domain – containing  TNFRSF  member 
FGF-inducible 14-kD protein (FN14), in 2001 (  Wiley et al., 
2001  ). FN14 occupancy leads to TRAF2-dependent activation 
of MAP kinases and the canonical and noncanonical NF-   B 
pathways (  Saitoh et al., 2003  ). Like many TNF family members, 
TWEAK has roles that vary among tissues, including enhance-
ment of proliferation, cell migration, expression and secretion 
of proinfl  ammatory molecules, and proangiogenic activity (  Wiley 
and Winkles, 2003  ). As its name suggests, TWEAK was origi-
nally found to be a rather poor cytotoxic agent that killed a 
  restricted number of tumor cell lines, usually in conjunction 
with a sensitizing agent. It has been difficult to pigeonhole 
a mechanism of action because cell death is mediated by differ-
ent pathways in different cell lines, with the mechanisms in-
cluding caspase-dependent apoptosis, cathepsin B  –  dependent 
necrosis, and indirect induction of apoptosis by induction of 
autocrine TNF     production (  Schneider et al., 1999  ;   Nakayama 
et al., 2003  ). 
  In this issue of   The Journal of Cell Biology  , Vince et al. 
(see p. 171) explore the consequences of TWEAK-FN14 sig-
naling in human tumor cells and fi  nd some unexpected simi-
larities (as well as key differences) between TWEAK and IAP 
antagonists. Their initial observation was that a high proportion 
of tumor cell lines express FN14. Consistent with previous yeast 
two-hybrid and GST-FN14 pulldown studies, pulldown of FN14 
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fact that cIAP1  –  TRAF2 levels were reduced and NF-   B  was 
activated just as in transformed cells. 
  Therefore, despite differences in the mechanistic details, 
there are remarkable similarities between stimulation with 
TWEAK and with IAP antagonists. One leitmotif is that the ac-
tivation of NF-   B  pathways  and  TNF    production stems from 
a reduction in cIAP1 and, in some cases, cIAP2 and TRAF2, a 
condition that can be termed cIAP defi  ciency (cIDE). Another is 
that cIDE sensitizes tumor cells to the cytotoxic effects of TNF   
alone. It is interesting in this light to reconsider the observation 
that TNF-R2 signals for cIAP1 autoubiquitination and ubiqui-
tination of TRAF2, their proteasome-mediated degradation, 
and sensitization of otherwise resistant cells to TNF     alone 
(  Li et al., 2002  ). Prevention of autoubiquitination with an E3-
defective cIAP1 mutant inhibited TNF   -induced  TRAF2  deg-
radation and cell death, demonstrating that in fact self-induced 
loss of cIAP1 and, perhaps, TRAF2 is proapoptotic. Reinforcing 
the similarities between these three stimuli, ligation of TNF-R2 
(as well as the TNFRSF members CD30 and CD40) caused 
 autocrine  TNF    production and TNF-R1  –  dependent death in a 
tumor cell line also susceptible to IAP antagonists and TWEAK 
(  Grell et al., 1999  ). 
  The following is a simplifi  ed framework that deals with 
elements common to signaling by IAP antagonists, TWEAK/
FN14, TNF    /TNF-R2, and perhaps other TNFRSF members 
(  Fig. 1  ). In this model, cIDE activates the canonical NF-   B 
pathway by allowing RIP to associate with preassembled TNF-R 
complexes, and the noncanonical NF-    B pathway by up-regulating 
NIK, which, as a target of cIAP1 and cIAP2 ubiquitination/
degradation (  Varfolomeev et al., 2007  ), is stabilized by their 
loss. TNF     is produced as a consequence of NF-   B  activation 
with a TWEAK-Fc receptor fusion protein also brought down 
TRAF2 and cIAP1 from tumor cell lysates, the latter probably 
brought into the complex by TRAF2. Things began to get inter-
esting with the observation that TWEAK signaling caused a 
gradual reduction of cIAP1, as previously noted (  Varfolomeev 
et al., 2007  ), and TRAF2, and although both molecules have E3 
activity neither were rescued by proteasome inhibitors. Rather, 
lysosomal inhibitors such as chloroquine, ammonium chloride, 
and a selective cathepsin B inhibitor prevented TWEAK-induced 
TRAF2 and, to a lesser extent, cIAP1 degradation. This was suf-
fi  ciently reminiscent of the behavior of IAP antagonists to ask if 
TWEAK-induced NF-    B activation is a consequence of cIAP1  –
  TRAF2 loss. Several lines of evidence suggest that it is. First, 
both cIAP1- and TRAF2-defi  cient transformed MEFs had low 
constitutive levels of cytoplasmic p100 and high levels of nuclear 
p52 and higher levels of phosphorylated I    B and p65, indicating 
activation of noncanonical and canonical NF-    B pathways, re-
spectively. In agreement with the IAP antagonist data, the en-
hanced noncanonical pathway was caused by stabilization of the 
p100-phosphorylating kinase NIK. How the canonical pathway 
was activated is unclear, but if the analogy with IAP antagonists 
holds, it may be caused by recruitment of RIP to preassembled 
TNF-R1 (TNF receptor 1) trimers (  Chan et al., 2000  ;   Vince 
et al., 2007  ). Second, enforced expression of TRAF2 and cIAP1, 
but neither alone, attenuated TWEAK-induced NF-   B  activa-
tion. Further establishing a link with IAP antagonists, TWEAK 
stimulation of susceptible tumor cells caused NF-   B – dependent 
TNF     production  and  TNF-R1/caspase-8 – dependent  death,  and 
TWEAK sensitized both long-term tumor lines and early-passage 
primary human tumors to killing by exogenous TNF   .  Primary 
cells were resistant to TWEAK/TNF     cytotoxicity despite the 
  Figure 1.       cIDE signaling: pathways leading to and emanating 
from cIAP reduction in sensitive tumor cells.   (A) Under steady-state 
conditions, cIAP1/2 ubiquitinates NIK with K48-linked chains, 
maintaining it and noncanonical NF-    B signaling at low levels. 
cIAP1/2 also prevents spontaneous association of RIP with pre-
existing TNF-R1  –  assembled trimers. The ability of death domain-
less TNFRSF members like CD30 and CD40 to kill by cIDE has not 
been directly examined but is indirectly supported by the ﬁ  nding 
that CD30 signaling can cause TRAF2 degradation (  Duckett and 
Thompson, 1997 ). (B) Stimulation results in cIAP autoubiquitination 
and degradation in either proteasomes (TNF    /TNF-R2 or IAP 
antagonists) or lysosomes (TWEAK/FN14). TRAF2 is also degraded 
after receptor-mediated but not IAP antagonist stimulation. This re-
sults in NIK stabilization and increases in noncanonical NF-    B 
activation and recruitment of RIP to TNF-R1 leading to canonical 
NF-    B activation. TNF     is produced and exported to the mem-
brane and secreted. (C) TNF     binds to and signals via TNF-R1. 
In the absence of cIAP, receptor-associated RIP is deubiquitinated 
by CYLD and does not gain K48-linked polyubiquitin, leaves the 
receptor, and assembles a death-initiating complex with FADD 
and caspase-8.     17 TWEAKING DEATH   • Ashwell 
(and presumably other signals) and binds TNF-R1. cIDE renders 
cells sensitive to TNF     alone because it facilitates release of RIP 
from the liganded TNF-R1 and the formation of an active and 
c-FLIP – resistant  RIP – FADD – caspase-8  complex  ( Wang  et  al., 
2008  ). Given that CYLD-mediated deubiquitination of RIP 
seems to be important for this process, it is possible that cIAPs 
antagonize RIP release by countering deubiquitination or that 
they ubiquitinate and target RIP for destruction and, thus, a re-
duction in cIAP levels would enhance the formation of the death 
initiator complex. It remains puzzling why primary cells, despite 
TWEAK-induced loss of cIAP1, are resistant to TNF   . Another 
question is, how are cIAP1 and TRAF2 marked for lysosomal 
destruction? The fact that proteasomes are not involved does not 
rule out ubiquitination as the fl  ag because ubiquitination can tar-
get proteins to lysosomes (  Urbe, 2005  ). As with all surprising 
and provocative observations, there are many more questions than 
answers, but the emerging theme that down-regulating cIAP levels 
has profound effects on tumor cell survival may ultimately prove 
to be profoundly useful. 
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